The Drugs Consultative Committee has sought the DGHS opinion and data on Merbromin’s manufacture and use before deciding on its continued inclusion under Schedule K
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.